154 related articles for article (PubMed ID: 9832291)
21. Topotecan-based combination chemotherapy for human malignant glioma.
Schmidt F; Schuster M; Streffer J; Schabet M; Weller M
Anticancer Res; 1999; 19(2A):1217-21. PubMed ID: 10368678
[TBL] [Abstract][Full Text] [Related]
22. Study on the sensitivity of primary tumor cells of patients with cervical cancer to chemotherapeutic combinations.
Qiu F; Zhao X
J BUON; 2018; 23(1):117-123. PubMed ID: 29552770
[TBL] [Abstract][Full Text] [Related]
23. Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
Boabang P; Kurbacher CM; Kohlhagen H; Waida A; Amo-Takyi BK
Anticancer Drugs; 2000 Nov; 11(10):843-8. PubMed ID: 11142692
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
25. Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.
Anzai H; Frost P; Abbruzzese JL
Cancer Res; 1992 Apr; 52(8):2180-5. PubMed ID: 1373105
[TBL] [Abstract][Full Text] [Related]
26. Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells.
Sunami T; Nishio K; Kanzawa F; Fukuoka K; Kudoh S; Yoshikawa J; Saijo N
Cancer Chemother Pharmacol; 1999; 43(5):394-401. PubMed ID: 10100595
[TBL] [Abstract][Full Text] [Related]
27. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
28. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.
Hahn SM; Liebmann JE; Cook J; Fisher J; Goldspiel B; Venzon D; Mitchell JB; Kaufman D
Cancer; 1993 Nov; 72(9):2705-11. PubMed ID: 8104682
[TBL] [Abstract][Full Text] [Related]
29. In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA).
Larsson R; Fridborg H; Kristensen J; Sundström C; Nygren P
Br J Cancer; 1993 May; 67(5):969-74. PubMed ID: 8494730
[TBL] [Abstract][Full Text] [Related]
30. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Cheng MF; Chatterjee S; Berger NA
Oncol Res; 1994; 6(6):269-79. PubMed ID: 7865902
[TBL] [Abstract][Full Text] [Related]
31. Clinical status and optimal use of topotecan.
Takimoto CH; Arbuck SG
Oncology (Williston Park); 1997 Nov; 11(11):1635-46; discussion 1649-51, 1655-7. PubMed ID: 9394364
[TBL] [Abstract][Full Text] [Related]
32. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line.
Goldwasser F; Bozec L; Zeghari-Squalli N; Misset JL
Anticancer Drugs; 1999 Feb; 10(2):195-201. PubMed ID: 10211550
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
Jonsson E; Fridborg H; Csóka K; Dhar S; Sundström C; Nygren P; Larsson R
Br J Cancer; 1997; 76(2):211-9. PubMed ID: 9231921
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
35. MGI 114: augmentation of antitumor activity when combined with topotecan.
Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald JR; Waters SJ; Von Hoff D
J Pediatr Hematol Oncol; 2000; 22(4):306-14. PubMed ID: 10959900
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
[TBL] [Abstract][Full Text] [Related]
37. Topotecan in cervical cancer.
Ackermann S; Beckmann MW; Thiel F; Bogenrieder T
Int J Gynecol Cancer; 2007; 17(6):1215-23. PubMed ID: 17997795
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients.
von Heideman A; Sandström M; Csoka K; Tholander B; Larsson R; Bergh J; Nygren P
Ann Oncol; 2000 Oct; 11(10):1301-7. PubMed ID: 11106120
[TBL] [Abstract][Full Text] [Related]
39. Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Nagourney RA; Sommers BL; Harper SM; Radecki S; Evans SS
Br J Cancer; 2003 Nov; 89(9):1789-95. PubMed ID: 14583785
[TBL] [Abstract][Full Text] [Related]
40. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.
Wahl AF; Donaldson KL; Mixan BJ; Trail PA; Siegall CB
Int J Cancer; 2001 Aug; 93(4):590-600. PubMed ID: 11477565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]